CAR-T cell therapy for ALL: Current challenges and future approaches
Dr Sara Ghorashian - University College London, London, UK
23 Jan 2020
CART-T cell therapy in young patients with relapsed/refractory ALL
Prof Peter Bader - Universitätsklinikum Frankfurt, Frankfurt, Germany
23 Jan 2020
The role of blinatumomab followed by HSCT in paediatric patients with ALL
Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy
23 Jan 2020
Long-term toxicities in paediatric ALL
Prof Kjeld Schmiegelow - University of Copenhagen, Copenhagen, Denmark
23 Jan 2020
Frontline therapy of ALL
Prof Hervé Dombret - University Paris Diderot, Paris, France
23 Jan 2020
BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL
Prof Hervé Dombret - University Paris Diderot, Paris, France
23 Jan 2020
Identifying cancer susceptibility genes in paediatric ALL
Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA
23 Jan 2020
Latest concepts in frontline therapy for paediatric ALL
Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA
23 Jan 2020
Dasatinib vs imatinib in the treatment of paediatric ALL
Dr Shuhong Shen - National Children's Medical Center, Shanghai, China
24 Dec 2019
Blinatumomab vs chemotherapy as post-reinduction therapy in HR/IR first relapse ...
Dr Patrick Brown - Johns Hopkins University, Baltimore, USA
10 Dec 2019
Blinatumomab demonstrates superior efficacy compared to chemotherapy in children...
Dr Patrick Brown - Johns Hopkins University, Baltimore, USA
10 Dec 2019
Tackling the increase in cancer cases worldwide
Prof Tezer Kutluk, Dr Eduardo Cazap
12 Jul 2019
